Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort (XVU-AV DAPT)

This study has been completed.
Harvard Clinical Research Institute
Bristol-Myers Squibb
Eli Lilly and Company
Daiichi Sankyo Inc.
Information provided by (Responsible Party):
Abbott Vascular Identifier:
First received: April 16, 2010
Last updated: September 11, 2013
Last verified: September 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2013
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)